Purpose：We aimed to build a predictive model for ADL, applicable to all patients admitted to a convalescent rehabilitation ward, that uses a simple index as explanatory variables, which is accessible early during hospitalization.Methods：We included 1153 patients admitted to our convalescent rehabilitation ward. Stepwise multiple regression analysis was conducted using 18 Functional Independence Measure (FIM) sub-items at admission, with sex, age, and time since onset as explanatory variables. The total FIM motor score was calculated by summing 13 motor sub-items at discharge. Cross-validation was performed on 85 participants, independent of the analysis group, to confirm the model's clinical applicability.Results：The multiple regression analysis results for the analysis group showed a significant equation with an R2 of 0.712. In the validation group with 85 patients, difference between the predicted and actual FIM scores at discharge was compared between the two groups, and a strong correlation of r=0.888 (p＜0.019 was observed, without any significant difference between the groups.Conclusion：This model is less labor intensive when constructing a prediction equation because the objective variable is easily obtained. Our findings indicate that other convalescent rehabilitation wards can develop prognostic models using their data and implement them clinically.

Purpose：We aimed to build a predictive model for ADL, applicable to all patients admitted to a convalescent rehabilitation ward, that uses a simple index as explanatory variables, which is accessible early during hospitalization.Methods：We included 1153 patients admitted to our convalescent rehabilitation ward. Stepwise multiple regression analysis was conducted using 18 Functional Independence Measure (FIM) sub-items at admission, with sex, age, and time since onset as explanatory variables. The total FIM motor score was calculated by summing 13 motor sub-items at discharge. Cross-validation was performed on 85 participants, independent of the analysis group, to confirm the model's clinical applicability.Results：The multiple regression analysis results for the analysis group showed a significant equation with an R2 of 0.712. In the validation group with 85 patients, difference between the predicted and actual FIM scores at discharge was compared between the two groups, and a strong correlation of r=0.888 (p＜0.01) was observed, without any significant difference between the groups.Conclusion：This model is less labor intensive when constructing a prediction equation because the objective variable is easily obtained. Our findings indicate that other convalescent rehabilitation wards can develop prognostic models using their data and implement them clinically.

Background: Fibrates have renal toxicity limiting their use in subjects with chronic kidney disease (CKD). However, pemafibrate has fewer toxic effects on renal function. In the present analysis, we evaluated the effects of pemafibrate on the renal function of diabetic subjects with or without CKD in a real-world clinical setting. Methods: We performed a sub-analysis of data collected during a multi-center, prospective, observational study of the effects of pemafibrate on lipid metabolism in subjects with type 2 diabetes mellitus complicated by hypertriglyceridemia (the PARM-T2D study). The participants were allocated to add pemafibrate to their existing regimen (ADD-ON), switch from their existing fibrate to pemafibrate (SWITCH), or continue conventional therapy (CTRL). The changes in estimated glomerular filtration rate (eGFR) over 52 weeks were compared among these groups as well as among subgroups created according to CKD status. Results: Data for 520 participants (ADD-ON, n=166; SWITCH, n=96; CTRL, n=258) were analyzed. Of them, 56.7% had CKD. The eGFR increased only in the SWITCH group, and this trend was also present in the CKD subgroup (P<0.001). On the other hand, eGFR was not affected by switching in participants with severe renal dysfunction (G3b or G4) and/or macroalbuminuria. Multivariate analysis showed that being older and a switch from fenofibrate were associated with elevation in eGFR (both P<0.05). Conclusion A switch to pemafibrate may be associated with an elevation in eGFR, but to a lesser extent in patients with poor renal function.

Objective: DNA methyltransferase 1 (DNMT1) is crucial to maintaining methylation during DNA replication and DNA repair. DNMT1 mutations have been identified in two neurological syndromes, including hereditary sensory and autonomic neuropathy type IE (HSAN IE) with dementia and hearing loss and autosomal dominant cerebellar ataxia, deafness and narcolepsy. It is likely that DNMT1 mutations lead to various symptoms of the central and peripheral nervous system. The aim of this study was to examine the clinical characteristics, especially the initial symptoms, in the cases of DNMT1 mutations. Methods: We investigated the clinical manifestation and examination findings of four cases of HSAN IE from one family with the DNMT1 mutation c.1531Y>C (p.Try511His). Results: All four cases exhibited sensory neuropathy, cerebellar ataxia, and hearing loss, all of which were demonstrated by the audiograms. The initial symptoms of the four cases included hearing loss (n=1), gait disturbance (n=1), and depressive mood (n=2). Depressive symptoms are reported in some cases with HSAN IE, however, there are currently no published reports that describe them as primary symptoms. The CSF orexin level was measured in three cases, revealing normal values in two cases and intermediate values in one case, in which the patient exhibited rapid eye movement (REM) sleep behavior disorder. Conclusion: Our findings suggest that in cases with HSAN IE or the DNMT1 mutation, psychiatric symptoms should be taken into account as one of the initial manifestations of the disease.

Objective: Combination therapy with glecaprevir and pibrentasvir (G/P) has been shown to provide a sustained virologic response (SVR) rate of >97% in patients with chronic hepatitis C virus (HCV) infection in the first published real-world Japanese data. However, a recently published study showed that the treatment was often discontinued in patients ≥75 years old, resulting in low SVR in intention-to-treat (ITT) analysis. Thus, our aim was to evaluate real-world data for G/P therapy in patients ≥75 years of age, the population density of which is high in “rural” regions.Patients and Methods: We conducted a multicenter study to assess the efficacy and safety of G/P therapy for chronic HCV infection, in the North Kanto area in Japan.Results: Of the 308 patients enrolled, 294 (95.5%) completed the treatment according to the protocol. In ITT and per-protocol analyses, the overall SVR12 rate was 97.1% and 99.7%, respectively. The old-aged patients group consisted of 59 participants, 56 of whom (94.9%) completed the scheduled protocol. Although old-aged patients tended to have non-SVR factors such as liver cirrhosis, history of HCC, and prior DAA therapies, the SVR12 rates in old-aged patients were 98.3% and 100% in the ITT and PP analyses, respectively. Of 308 patients enrolled, adverse events were observed in 74 patients (24.0%), with grade ≥3 events in 8 patients (2.6%). There was no significant difference in any grade and grade ≥3 adverse events between the old-aged group and the rest of the study participants. Only one patient discontinued the treatment because of adverse events.Conclusion: G/P therapy is effective and safe for old-aged patients.